TY - JOUR
T1 - Pharmacological treatments for thyroid eye disease
AU - Modjtahedi, Sara P.
AU - Modjtahedi, Bobeck S.
AU - Mansury, Ahmad M.
AU - Selva, Dinesh
AU - Douglas, Raymond S.
AU - Goldberg, Robert A.
AU - Leibovitch, Igal
PY - 2006
Y1 - 2006
N2 - Thyroid eye disease (TED), which affects the majority of patients with Grave's disease, is associated with significant ophthalmic morbidity. In patients with mild disease, supportive treatment with lubricating medication can be sufficient. However, in patients with severe TED and disfiguring proptosis or sight-threatening neuropathy, more aggressive medical or surgical interventions are necessary. Corticosteroids remain the preferred pharmacological treatment modality in the majority of patients with an active inflammatory component. Other immunosuppressive drugs in combination with corticosteroids may be helpful in patients with corticosteroid-resistant TED. Newer agents such as somatostatin analogues have not shown to be of significant clinical benefit; however, initial studies on the use of antioxidants and cytokine antagonists are encouraging.
AB - Thyroid eye disease (TED), which affects the majority of patients with Grave's disease, is associated with significant ophthalmic morbidity. In patients with mild disease, supportive treatment with lubricating medication can be sufficient. However, in patients with severe TED and disfiguring proptosis or sight-threatening neuropathy, more aggressive medical or surgical interventions are necessary. Corticosteroids remain the preferred pharmacological treatment modality in the majority of patients with an active inflammatory component. Other immunosuppressive drugs in combination with corticosteroids may be helpful in patients with corticosteroid-resistant TED. Newer agents such as somatostatin analogues have not shown to be of significant clinical benefit; however, initial studies on the use of antioxidants and cytokine antagonists are encouraging.
UR - http://www.scopus.com/inward/record.url?scp=33748886126&partnerID=8YFLogxK
U2 - 10.2165/00003495-200666130-00003
DO - 10.2165/00003495-200666130-00003
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 16978034
AN - SCOPUS:33748886126
VL - 66
SP - 1685
EP - 1700
JO - Drugs
JF - Drugs
SN - 0012-6667
IS - 13
ER -